Drug Trial Radar · NCT07629440
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,230
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
Jun 5, 2029
Study completion Jun 5, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 211 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. It will also assess how the new vaccine works in comparison to the one that is currently in use when given with other childhood vaccines. To measure how the new pneumococcal vaccine compares to the current one, blood samples will be used to measure the body's ability to create proteins to fight those germs. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are three groups in this study. All participants will be assigned to one of the three groups. This study is seeking participants who are: * infants who are 2 months of age in Group 1; * infants who are 2 to 6 months of age in Groups 2 and 3; and * said to be healthy by the study doctor About 3000 infants will be assigned to Group 1. The infants in this group will have a 1 in 2 chance (50%) of receiving either PG4 (new vaccine) or 20vPnC (currently in use) into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. About 140 infants from outside the United States will be assigned to Group 2. The infants in this group will have a 1 in 2 chance (50%) of receiving either PG4 or 20vPnC into the left thigh muscle at 2 to 6, 3 to 8, 4 to 10, and 12 to 15 months of age. About 90 infants from outside the United States will be assigned to Group 3. The infants in Group 3 will have a 1 in 3 chance (33%) of receiving either PG4 into the left thigh muscle, PG4 under the skin of the left thigh, or 20vPnC into the left thigh muscle at 2 to 6, 3 to 8, 4 to 10, and 12 to 15 months of age. Infants in Group 1 will take part in this study for about 16 to 19 months (about 1 and a half years). Infants in Groups 2 and 3 will take part in this study for 12 to 21 months (about 1 to 1 and a half years). During this time, infants will have 6 study clinic visits and 1 phone call. At these study clinic visits, parent(s)/legal guardian(s) will be asked if the infant experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine. Infants will have 3 blood samples collected.
Conditions
- Pneumococcal Disease
Interventions
PG4Biological
Multivalent Pneumococcal Vaccine
20-valent pneumococcal conjugate vaccine (20vPnC)Biological
20-valent pneumococcal conjugate vaccine (20vPnC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting local reactions within 7 days after each doseTime frame: Day 7
- Percentage of participants reporting systemic events within 7 days after each doseTime frame: Day 7
- Percentage of participants reporting adverse events (AEs) from Dose 1 to 1 month after Dose 3Time frame: Dose 1 to 1 month after Dose 3
- Percentage of participants reporting AEs from Dose 4 to 1 month after Dose 4Time frame: Dose 4 to 1 month after Dose 4
- Percentage of participants reporting serious adverse events (SAEs)Time frame: Dose 1 to 6 months after Dose 4
- Differences in percentages of participants with predefined pneumococcal specific immunoglobulin G (IgG) concentrations 1 month after Dose 3Time frame: 1 month after Dose 3
- Pneumococcal IgG geometric mean concentrations (GMCs) 1 month after Dose 4Time frame: 1 month after Dose 4
Locations
134 sites in 3 countries. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics, LLC Birmingham Pediatric Associates
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham - School of Medicine
Birmingham, Alabama · Recruiting
Northwest Arkansas Pediatric Clinic
Fayetteville, Arkansas · Recruiting
The Children's Clinic of Jonesboro, P.A.
Jonesboro, Arkansas · Recruiting
Helios Clinical Research
Sherwood, Arkansas · Recruiting
Advanced Research Center, Inc.
Anaheim, California · Recruiting
San Gabriel Woman's Health
Arcadia, California · Recruiting
Coast Clinical Research, LLC
Bellflower, California · Recruiting
Family Medical Clinic
El Monte, California · Recruiting
Clinical Research of Central California
Fresno, California · Recruiting
Investigational Drug Services, Bowyer Pharmacy
Los Angeles, California · Not yet recruiting
Ronald Reagan UCLA Medical Center
Los Angeles, California · Not yet recruiting
UCLA (outpatient clinic)
Los Angeles, California · Not yet recruiting
UCLA
Los Angeles, California · Not yet recruiting
SeraCollection Research Services, LLC
Montebello, California · Recruiting
Bailony Pediatrics
National City, California · Recruiting
Stanford University Medical Center
Palo Alto, California · Not yet recruiting
Childrens Hospital of Colorado
Aurora, Colorado · Recruiting
Direct Helpers Research Center
Hialeah, Florida · Recruiting
C & R Research Services USA
Homestead, Florida · Recruiting
Florida Pharmaceutical Research and Associates, Inc.
Miami, Florida · Recruiting
International Research II, LLC.
Miami, Florida · Not yet recruiting
Bioresearch Partner
Miami, Florida · Recruiting
Gold Coast Health Research Center, LLC
Miami, Florida · Recruiting
Dade Research Center
Miami, Florida · Recruiting
Vasconcello-Cohen MD Research, LLC.
Miami, Florida · Recruiting
Barroso Medical Services LLC
Miami Lakes, Florida · Recruiting
Riveldi and Associates
Miami Lakes, Florida · Recruiting
Eminent Clinical Research and Associates
North Lauderdale, Florida · Recruiting
Cordova Research Institute LLC
Sweetwater, Florida · Recruiting
South Tampa Center for Advanced Healthcare- USF Health
Tampa, Florida · Recruiting
USF Health
Tampa, Florida · Recruiting
USF Health Department of Pediatrics The Chalsty Clinics at the Curran Children's Health Center (CMS)
Tampa, Florida · Recruiting
Children's Health Center
Tampa, Florida · Recruiting
ObjectiveHealth Clinical Research LLC - Chamblee
Chamblee, Georgia · Recruiting
Altruistic Clinical Research Global
Norcross, Georgia · Recruiting
Medical Research Partners
Ammon, Idaho · Recruiting
Bingham Memorial Hospital
Blackfoot, Idaho · Recruiting
ASR, LLC
Boise, Idaho · Recruiting
Leavitt Clinical Research
Idaho Falls, Idaho · Recruiting
Showing 40 of 134 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.